A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Hollenbach, Paul W ^a   Nguyen, Aaron N ^a   Brady, Helen ^a   Williams, Michelle ^b   Ning, Yuhong ^a   Richard, Normand ^a   Krushel, Leslie ^b   Aukerman, Sharon L ^a   Heise, Carla ^a   MacBeth, Kyle J ^a  

^a CELGENE CORPORATION   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA; DNA MARKER; DNA METHYLTRANSFERASE 1; NUCLEIC ACID; RNA; ANTINEOPLASTIC ANTIMETABOLITE; DMAP1 PROTEIN, HUMAN; DRUG DERIVATIVE; REPRESSOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL LINE; CELL VIABILITY; CONCENTRATION (PARAMETERS); DNA DAMAGE; DNA METHYLATION; DRUG MECHANISM; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MITOSIS; PROTEIN SYNTHESIS; ACUTE DISEASE; CELL STRAIN HL 60; CELL SURVIVAL; COMPARATIVE STUDY; DNA MICROARRAY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION; GENETICS; METABOLISM; METHODOLOGY; MYELOID LEUKEMIA; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ACUTE DISEASE; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AZACITIDINE; BLOTTING, WESTERN; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GENE EXPRESSION; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN BIOSYNTHESIS; REPRESSOR PROTEINS;

EID: 77749302093     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009001     Document Type: Article

References (37)

1. Cataldo VD, Cortes J, Quintás-Cardama A (2009) Azacitidine for the treatment of myelodysplastic syndrome. Expert Rev Anticancer Ther 9: 875-884.
2. Saba HI (2007) Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag 3: 807-817.
3. Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37-50.
4. Li LH, Olin EJ, Buskirk HH, Reineke LM (1970) Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res 30: 2760-2769.
5. Glover AB, Leyland-Jones B (1987) Biochemistry of azacitidine: a review. Cancer Treat Rep 71: 959-964.
6. Stresemann C, Bokelmann I, Mahlknecht U, Lyko F (2008) Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther 7: 2998-3005.
7. Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, et al. (2005) 5-Azadeoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 25: 4727-4741.
8. Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F (2006) Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 66: 2794-2800.
9. Flotho C, Claus R, Batz C, Schneider M, Sandrock I, et al. (2009) The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23: 1019-1028.
10. Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD (2008) DNA methylation inhibitor 5-Aza-2′-deoxycytidine induces reversible genomewide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol 28: 752-771.
11. Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, et al. (2007) 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther 6: 1718-1727.
12. Kantarjian H, Issa J-PJ, Rosenfeld CS, Bennett JM, Albitar M, et al. (2006) Decitabine improves patient outcomes in myelodyplastic syndromes: results of a phase III randomized study. Cancer 106: 1794-1803.
13. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, et al. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20: 2429-2440.
14. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, et al. (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10: 223-232.
15. Wijermans P, Suciu S, Baila L, Platzbecker U, Giagounidis A, et al. (2008) Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: Final results of the randomized phase III study (06011) of the EORTC leukemia and german MDS study groups [abstract]. Blood 112: Abstract 226.
16. Griffiths EA, Gore SD (2008) DNA methyltransferase inhibitors: class effect or unique agents? Leuk Lymphoma 49: 650-651.
17. Cihák A, Weiss JW, Pitot HC (1974) Characterization of polyribosomes and maturation of ribosomal RNA in hepatoma cells treated with 5-azacytidine. Cancer Res 34: 3003-3009.
18. Reichman M, Penman S (1973) The mechanism of inhibition of protein synthesis by 5-azacytidine in HeLa cells. Biochim Biophys Acta 324: 282-289.
19. Cihák A (1974) Biological effects of 5-azacytidine in eukaryotes. Oncology 30: 405-422.
20. Lu LJ, Randerath K (1980) Mechanism of 5-azacytidine-induced transfer RNA cytosine-5-methyltransferase deficiency. Cancer Res 40: 2701-2705.
21. Qin T, Jelinek J, Si J, Shu J, Issa JP (2009) Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood 113: 659-667.
22. Marcucci G, Silverman L, Eller M, Lintz L, Beach CL (2005) Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 45: 597-602.
23. Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J (2008) Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol 61: 759-766.
24. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, et al. (2008) Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 25: 3884-3891.
25. Hershko A, Mamont P, Shields R, Tomkins GM (1971) "Pleiotypic response". Nat New Biol 232: 206-211.
26. Bennett J, Ehrke J, Fadale P, Dave C, Mihich E (1978) Immunosuppressive effects of methylglyoxal-bis(guanylhydrazone) on mouse bone marrow and spleen cells and their antagonism by spermidine. Biochem Pharmacol 27: 1555-1560.
27. Adams RL, Fulton J, Kirk D (1982) The effect of 5-azadeoxycytidine on cell growth and DNA methylation. Biochim Biophys Acta 697: 286-294.
28. Momparler RL, Momparler LF, Samson J (1984) Comparison of the antileukemic activity of 5-AZA-2′-deoxycytidine, 1-beta-D- arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leukemia Res 8: 1043-1049.
29. Momparler RL, Samson J, Momparler LF, Rivard GE (1984) Cell cycle effects and cellular pharmacology of 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol 13: 191-194.
30. Gorczyca W, Gong J, Ardelt B, Traganos F, Darzynkiewicz Z (1993) The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res 53: 3186-3192.
31. Murakami T, Li X, Gong J, Bhatia U, Traganos F, Darzynkiewicz Z (1995) Induction of apoptosis by 5-azacytidine: drug concentration-dependent differences in cell cycle specificity. Cancer Res 55: 3093-3098.
32. Khong T, Sharkey J, Spencer A (2008) The effect of azacitidine on interleukin-6 signaling and nuclear factor-κB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica 93: 860-869.
33. Jiemjit A, Fandy TE, Carraway H, Bailey KA, Baylin S, et al. (2008) p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene 27: 3615-3623.
34. Lavelle D, DeSimone J, Hankewych M, Kousnetzova T, Chen YH (2003) Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/ M phase via the p38 MAP kinase pathway. Leukemia Res 27: 999-1007.
35. Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, et al. (2007) Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res 13: 4225-4232.
36. Berg T, Guo Y, Abdelkarim M, Fliegauf M, Lübbert M (2007) Reversal of p15/ INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. Leukemia Res 31: 497-506.
37. Schmelz K, Wagner M, Dörken B, Tamm I (2005) 5-Aza-2′- deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer 114: 683-695.